Velaglucerase alfa
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1. It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme. It is manufactured by Shire plc.
The most common side effects include abdominal pain, headache, dizziness, bone pain, arthralgia, back pain, infusion-related reactions, asthenia or fatigue, and pyrexia or increased body temperature.
Velaglucerase alfa was approved for medical use in the United States in February 2010, and in the European Union in August 2010.